COMMUNIQUÉS West-GlobeNewswire
-
Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering
06/03/2026 -
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/03/2026 -
Artelo Biosciences Announces Reverse Stock Split
06/03/2026 -
Tangram Therapeutics annonce l’administration de la première dose à un participant dans le cadre de l’essai RESTORE-MASH de phase I/II portant sur le TGM-312, un nouveau médicament expérimental à base d’ARNi
06/03/2026 -
Anathapindika Spotlight Shines on Rare Disease Day (and How Detoxification Can Help)
06/03/2026 -
Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
06/03/2026 -
Catheter Precision’s LockeT Suture Retention Device to be Featured in Live Cases at ISLAA 2026
06/03/2026 -
Claritas iPET™ Approved by Australia TGA to Supply the Medical Software Device for Image Processing Enabling Diagnostic Quality Images from Short Scan Time and/or Low Dose PET, PET-CT/MRI Scans
06/03/2026 -
Intended Retirement of Independent Non-executive Director and changes of composition of board committees
06/03/2026 -
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
06/03/2026 -
Fagron publishes its Annual Report 2025
06/03/2026 -
Paingone Plus TENS Pen Featured in 2026 Consumer Report Examining FDA Clearance Status, TENS Pain Therapy Research, and Portable Pain Relief Device Verification
06/03/2026 -
Quipt Home Medical Receives Final Order Approving Arrangement
06/03/2026 -
Rakovina Announces Closing of $1 Million Debenture Unit Private Placement and Debt Settlement Agreements
06/03/2026 -
aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update
05/03/2026 -
COSCIENS Provides Strategic Update
05/03/2026 -
Nova Leap Health Corp. Posts Fourth Quarter and Record Full-Year 2025 Revenues and Adjusted EBITDA
05/03/2026 -
ArriVent BioPharma Reports Full Year 2025 Financial Results
05/03/2026 -
President & CEO Letter to Shareholders
05/03/2026
Pages